Nucleome Therapeutics, a leading UK biotech firm that specialises in decoding the dark genome's non-coding DNA regions to develop precision medicines for autoimmune diseases like multiple sclerosis, lupus, and rheumatoid arthritis, purchase LTE research-grade autoclave to assist with research. Click to read more.
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Woodcock set to retire from FDA in early 2024—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
The U.S. company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.